CY1113108T1 - LEVODOPA BASIC PRODUCT, HIS COMPOSITIONS, AND USES - Google Patents

LEVODOPA BASIC PRODUCT, HIS COMPOSITIONS, AND USES

Info

Publication number
CY1113108T1
CY1113108T1 CY20121100822T CY121100822T CY1113108T1 CY 1113108 T1 CY1113108 T1 CY 1113108T1 CY 20121100822 T CY20121100822 T CY 20121100822T CY 121100822 T CY121100822 T CY 121100822T CY 1113108 T1 CY1113108 T1 CY 1113108T1
Authority
CY
Cyprus
Prior art keywords
compositions
levodopa
basic product
treatment
methods
Prior art date
Application number
CY20121100822T
Other languages
Greek (el)
Inventor
Jia-Ning Xiang
Xuedong Dai
Cindy X Zhou
Jianhua Li
Mark Q Nguyen
Original Assignee
Xenoport, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenoport, Inc. filed Critical Xenoport, Inc.
Publication of CY1113108T1 publication Critical patent/CY1113108T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)

Abstract

Παρέχονται (2R)-2-Φαινυλκαρβονυλοξυπροπυλ (2S)-2-αμινο-3(3,4-διϋδροξυφαινυλ)προπανοϊκό μεσυλικό και κρυσταλλική μορφή αυτού, μέθοδοι κατασκευής αυτού, φαρμακευτικές συνθέσεις αυτού, και μέθοδοι χρήσης αυτού για τη θεραπευτική αγωγή ασθενειών ή διαταραχών όπως νόσου Parkinson.(2R) -2-Phenylcarbonyloxypropyl (2S) -2-amino-3 (3,4-dihydroxyphenyl) propanoate mesylate and crystalline form, methods of its manufacture, pharmaceutical compositions, and methods of its use for the treatment or treatment of patients such as Parkinson's disease.

CY20121100822T 2005-12-05 2012-09-12 LEVODOPA BASIC PRODUCT, HIS COMPOSITIONS, AND USES CY1113108T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74187605P 2005-12-05 2005-12-05
EP06844799A EP1959948B1 (en) 2005-12-05 2006-12-04 Levodopa prodrug mesylate, compositions thereof, and uses thereof

Publications (1)

Publication Number Publication Date
CY1113108T1 true CY1113108T1 (en) 2016-04-13

Family

ID=38123406

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100822T CY1113108T1 (en) 2005-12-05 2012-09-12 LEVODOPA BASIC PRODUCT, HIS COMPOSITIONS, AND USES

Country Status (21)

Country Link
US (5) US7563821B2 (en)
EP (1) EP1959948B1 (en)
JP (1) JP5153641B2 (en)
KR (1) KR101396639B1 (en)
CN (1) CN101365439B (en)
AU (1) AU2006322051B2 (en)
BR (1) BRPI0619425A2 (en)
CA (1) CA2631643C (en)
CY (1) CY1113108T1 (en)
DK (1) DK1959948T3 (en)
ES (1) ES2391575T3 (en)
HK (1) HK1121381A1 (en)
IL (1) IL191937A (en)
NO (1) NO20082768L (en)
NZ (1) NZ569485A (en)
PL (1) PL1959948T3 (en)
PT (1) PT1959948E (en)
RU (1) RU2429223C2 (en)
TW (1) TWI403493B (en)
WO (1) WO2007067495A2 (en)
ZA (1) ZA200805511B (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005121070A1 (en) * 2004-06-04 2005-12-22 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
NZ551511A (en) * 2004-06-04 2010-09-30 Xenoport Inc Levodopa prodrugs, and compositions and uses thereof
BRPI0619425A2 (en) * 2005-12-05 2011-10-04 Xenoport Inc levedopa prodrug mesylate, pharmaceutical composition, method of preparing (2r) -2-phenyl carbonyloxy propyl mesylate (2s) -2-amino-3- (3,4-dihydroxy phenyl) propanoate and use of said compound
WO2008034087A2 (en) * 2006-09-15 2008-03-20 Xenoport, Inc. Treating schizophrenia with combinations of levodopa and an antipsychotic agent
WO2008079387A1 (en) * 2006-12-21 2008-07-03 Xenoport, Inc. Catechol protected levodopa diester prodrugs, compositions, and methods of use
WO2008076458A1 (en) 2006-12-21 2008-06-26 Xenoport, Inc. Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use
CN102186467B (en) 2008-10-17 2014-06-04 特色疗法股份有限公司 Pharmaceutical compositions with attenuated release of phenolic opioids
EP2349973A2 (en) * 2008-10-20 2011-08-03 XenoPort, Inc. Methods of synthesizing a levodopa ester prodrug
US8399513B2 (en) 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
KR20120006059A (en) * 2009-04-17 2012-01-17 메르츠 파마 게엠베하 운트 코. 카가아 Synthesis of 1-amino-1,3,3,5,5-pentamethylcyclohexane mesylate
SG179026A1 (en) 2009-09-08 2012-04-27 Signature Therapeutics Inc Compositions comprising enzyme-cleavable ketone-modified opioid prodrugs and optional inhibitors thereof
US8435562B2 (en) 2009-11-09 2013-05-07 Xenoport, Inc. Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
EA026419B1 (en) 2010-03-04 2017-04-28 Орион Корпорейшн Use of levodopa, carbidopa and entacapone for treating parkinson's disease
WO2011133178A1 (en) 2010-04-21 2011-10-27 Pharmacofore, Inc Compositions comprising enzyme-cleavable phenol-modified tapentadol prodrug
US20110262355A1 (en) 2010-04-21 2011-10-27 Jenkins Thomas E Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof
US20130059914A1 (en) 2010-04-21 2013-03-07 Signature Therapeutics, Inc. Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof
US10150792B2 (en) 2010-11-08 2018-12-11 Synthonics, Inc. Bismuth-containing compounds, coordination polymers, methods for modulating pharmacokinetic properties of biologically active agents, and methods for treating patients
PL2647619T3 (en) 2010-12-02 2015-08-31 Ono Pharmaceutical Co Novel compound and medical use thereof
AU2012205733B2 (en) 2011-01-11 2015-10-08 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable oxycodone prodrug
WO2012096886A1 (en) 2011-01-11 2012-07-19 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable oxycodone prodrug
US9139612B2 (en) 2011-03-09 2015-09-22 Signature Therapeutics, Inc. Active agent prodrugs with heterocyclic linkers
WO2012122420A2 (en) 2011-03-09 2012-09-13 Pharmacofore, Inc. Opioid prodrugs with heterocyclic linkers
CA2853251A1 (en) * 2011-10-24 2013-05-02 Endo Pharmaceuticals Solutions Inc. Implantable rasagiline compositions and methods of treatment thereof
US9575244B2 (en) 2013-01-04 2017-02-21 Bal Makund Dhar Light guide apparatus and fabrication method thereof
FR3008411B1 (en) 2013-07-12 2015-07-03 Servier Lab NOVEL 3 - [(3 - {[4- (4-MORPHOLINYLMETHYL) -1H-PYRROL-2-YL] METHYLENE} -2-OXO-2,3-DIHYDRO-1H-INDOL-5-YL) METHYL SALT ] -1,3-THIAZOLIDINE-2,4-DIONE, ITS PREPARATION, AND THE FORMULATIONS CONTAINING IT
CN103554078B (en) * 2013-11-22 2016-03-02 浙江安赛生物科技有限公司 Low grade aldehyde (C 2-C 10) synthetic method of propylene glycol acetal
AU2015335941B2 (en) * 2014-10-21 2021-04-01 Abbvie Inc. Carbidopa and L-dopa prodrugs and their use to treat Parkinson's disease
WO2016179540A1 (en) 2015-05-06 2016-11-10 Synagile Corporation Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use
KR20210134838A (en) 2016-07-14 2021-11-10 크리네틱스 파마슈티칼스, 인크. Somatostatin modulators and uses thereof
WO2019097120A1 (en) 2017-11-16 2019-05-23 Orion Corporation New use and pharmaceutical dosage forms
EP3813831B1 (en) * 2018-09-21 2023-03-22 Amneal Complex Products Research LLC Extended release compositions comprising trihexyphenidyl
US20220267295A1 (en) * 2019-07-17 2022-08-25 Crinetics Pharmaceuticals, Inc. Crystalline forms of somatostatin modulators
EP4210700A1 (en) 2020-09-09 2023-07-19 Crinetics Pharmaceuticals, Inc. Formulations of a somatostatin modulator
US20240009433A1 (en) * 2020-09-11 2024-01-11 Synagile Corporation Methods for continuous oral drug delivery

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3962414A (en) 1972-04-27 1976-06-08 Alza Corporation Structured bioerodible drug delivery device
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3811444A (en) 1972-12-27 1974-05-21 Alza Corp Bioerodible ocular device
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
DE2336218C3 (en) 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Oral dosage form
US4038411A (en) * 1973-09-25 1977-07-26 Merck & Co., Inc. Antihypertensive amino acid esters
US3983138A (en) 1973-09-25 1976-09-28 Merck & Co., Inc. Amino acid esters
US3992518A (en) 1974-10-24 1976-11-16 G. D. Searle & Co. Method for making a microsealed delivery device
US4093709A (en) 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4079038A (en) 1976-03-05 1978-03-14 Alza Corporation Poly(carbonates)
US4066747A (en) 1976-04-08 1978-01-03 Alza Corporation Polymeric orthoesters housing beneficial drug for controlled release therefrom
US4070347A (en) 1976-08-16 1978-01-24 Alza Corporation Poly(orthoester) co- and homopolymers and poly(orthocarbonate) co- and homopolymers having carbonyloxy functionality
FR2365341A1 (en) 1976-09-28 1978-04-21 Synthelabo L- (PHENYL-3 AMINO-2 PROPIONYLOXY) -2 ACETIC DERIVATIVES
US4180509A (en) * 1977-07-01 1979-12-25 Merrell Toraude Et Compagnie α-Ethynyl tryptophanes
US4311706A (en) 1980-01-22 1982-01-19 Interx Research Corporation Novel dopa/dopamine prodrugs
JPS5824547A (en) 1981-08-06 1983-02-14 Nippon Zoki Pharmaceut Co Ltd Novel amino acid derivative
US4914222A (en) 1983-08-29 1990-04-03 Merck & Co., Inc. Crystalline salts of L or (S)-3-(3,4-dihydroxyphenyl)-2-methylalanine esters and process
LU85757A1 (en) 1985-02-04 1986-09-02 Univ Catholique Louvain NOVEL L-DOPA DERIVATIVES, METHODS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS RELATING TO SUCH COMPOUNDS
US4873263A (en) 1985-12-30 1989-10-10 Merck & Co., Inc. Rectally absorbable form of L-dopa
US4771073A (en) 1985-12-30 1988-09-13 Merck & Co., Inc. Rectally absorbable form of L-dopa
US4663349A (en) 1985-12-30 1987-05-05 Merck & Co., Inc. Rectally absorbable form of L-dopa
JPS62258347A (en) * 1986-05-02 1987-11-10 Banyu Pharmaceut Co Ltd L-threo-3-(3,4-dihydroxyphenyl)-n-methylserine in anhydrous crystal form
ES2042520T3 (en) 1986-06-10 1993-12-16 Chiesi Farma Spa PHARMACEUTICAL COMPOSITIONS CONTAINING LEVODOPA METHYL ESTER, PREPARATION AND THERAPEUTIC APPLICATIONS THEREOF.
US4983400A (en) 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
DK406686D0 (en) * 1986-08-26 1986-08-26 Hans Bundgaard carboxylic acid derivatives
US5283352A (en) * 1986-11-28 1994-02-01 Orion-Yhtyma Oy Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same
JPH02138A (en) 1987-09-18 1990-01-05 Banyu Pharmaceut Co Ltd L-dopa derivative
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
DE3930696A1 (en) 1989-09-14 1991-03-28 Hoechst Ag GALLENSAEUREDERIVATE, METHOD FOR THE PRODUCTION THEREOF, USE AS MEDICAMENT
US5190763A (en) * 1990-05-07 1993-03-02 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5057321A (en) * 1990-06-13 1991-10-15 Alza Corporation Dosage form comprising drug and maltodextrin
US5128145A (en) * 1990-06-13 1992-07-07 Alza Corporation Dosage form for Parkinson's disease, spasticity and muscle spasms
US5827819A (en) 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
US5332576A (en) * 1991-02-27 1994-07-26 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5607969A (en) 1992-12-24 1997-03-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem L-DOPA ethyl ester to treat Parkinson's disease
JPH07278076A (en) * 1994-04-12 1995-10-24 Ajinomoto Co Inc Crystallization of l-phenylalanine monomethyl sulfate
US5840756A (en) 1995-07-21 1998-11-24 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition of L-DOPA ester
GB2348371B (en) 2000-03-14 2001-04-04 Soares Da Silva Patricio Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease
AU2002243204A1 (en) 2000-10-06 2002-06-11 Xenoport, Inc. Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
WO2002028882A1 (en) 2000-10-06 2002-04-11 Xenoport, Inc. Bile acid prodrugs of l-dopa and their use in the sustained treatment of parkinsonism
IL159812A0 (en) 2001-07-12 2004-06-20 Teva Pharma Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester in a controlled release core
WO2003041646A2 (en) 2001-11-13 2003-05-22 Teva Pharmaceutical Industries, Ltd. L-dopa ethyl ester salts and uses thereof
US20030158254A1 (en) 2002-01-24 2003-08-21 Xenoport, Inc. Engineering absorption of therapeutic compounds via colonic transporters
US7101912B2 (en) * 2002-12-06 2006-09-05 Xenoport, Inc. Carbidopa prodrugs and derivatives, and compositions and uses thereof
US20050209181A1 (en) * 2003-11-05 2005-09-22 Huda Akil Compositions and methods for diagnosing and treating mental disorders
NZ551511A (en) 2004-06-04 2010-09-30 Xenoport Inc Levodopa prodrugs, and compositions and uses thereof
WO2005121070A1 (en) 2004-06-04 2005-12-22 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
DE102005022276A1 (en) 2005-05-13 2006-11-16 Ellneuroxx Ltd. Derivatives of dihydroxyphenylalanine
BRPI0619425A2 (en) 2005-12-05 2011-10-04 Xenoport Inc levedopa prodrug mesylate, pharmaceutical composition, method of preparing (2r) -2-phenyl carbonyloxy propyl mesylate (2s) -2-amino-3- (3,4-dihydroxy phenyl) propanoate and use of said compound
US9603941B2 (en) 2006-01-24 2017-03-28 Minghui Chai Method of preparing dendritic drugs
WO2008034087A2 (en) 2006-09-15 2008-03-20 Xenoport, Inc. Treating schizophrenia with combinations of levodopa and an antipsychotic agent
WO2008076458A1 (en) 2006-12-21 2008-06-26 Xenoport, Inc. Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use
WO2008079387A1 (en) 2006-12-21 2008-07-03 Xenoport, Inc. Catechol protected levodopa diester prodrugs, compositions, and methods of use
US8399513B2 (en) 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
EP2349973A2 (en) 2008-10-20 2011-08-03 XenoPort, Inc. Methods of synthesizing a levodopa ester prodrug
US8435562B2 (en) 2009-11-09 2013-05-07 Xenoport, Inc. Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use

Also Published As

Publication number Publication date
IL191937A (en) 2014-07-31
CA2631643A1 (en) 2007-06-14
JP5153641B2 (en) 2013-02-27
NO20082768L (en) 2008-06-24
CA2631643C (en) 2015-07-07
AU2006322051B2 (en) 2011-09-29
US20070225366A1 (en) 2007-09-27
IL191937A0 (en) 2009-08-03
RU2429223C2 (en) 2011-09-20
NZ569485A (en) 2011-06-30
KR101396639B1 (en) 2014-05-21
US7968597B2 (en) 2011-06-28
EP1959948A2 (en) 2008-08-27
DK1959948T3 (en) 2012-08-20
JP2009520690A (en) 2009-05-28
US20090326067A1 (en) 2009-12-31
BRPI0619425A2 (en) 2011-10-04
TW200804239A (en) 2008-01-16
ZA200805511B (en) 2010-02-24
CN101365439B (en) 2012-12-26
PT1959948E (en) 2012-09-12
US8193242B2 (en) 2012-06-05
WO2007067495A3 (en) 2007-09-27
EP1959948B1 (en) 2012-07-18
PL1959948T3 (en) 2012-12-31
US20120296109A1 (en) 2012-11-22
RU2008127312A (en) 2010-01-20
US7563821B2 (en) 2009-07-21
CN101365439A (en) 2009-02-11
HK1121381A1 (en) 2009-04-24
US7893105B2 (en) 2011-02-22
US20110111062A1 (en) 2011-05-12
US20090156679A1 (en) 2009-06-18
KR20080073365A (en) 2008-08-08
AU2006322051A1 (en) 2007-06-14
WO2007067495A2 (en) 2007-06-14
ES2391575T3 (en) 2012-11-27
TWI403493B (en) 2013-08-01

Similar Documents

Publication Publication Date Title
CY1113108T1 (en) LEVODOPA BASIC PRODUCT, HIS COMPOSITIONS, AND USES
CL2009000349A1 (en) Compounds derived from 4,5-dihydro-oxazol-2-ylamine; preparation procedure; pharmaceutical composition; and its use for the treatment of Alzheimer's disease.
CY1117326T1 (en) CATEGOLAMINE PRODUCT USEFUL FOR PARKINSON'S DISEASE TREATMENT
CY1121781T1 (en) RASAGILLINE EXTENDED-RELEASE PHARMACEUTICAL FORM AND USES THEREOF
EA201690265A3 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING SUBSTITUTED ACYLANILIDES
CY1108843T1 (en) 3,11B CIS DIMRODETRETRAVENASINE FOR THE TREATMENT OF SCHIZOPHRENIA AND OTHER PSYCHOLOGIES
CY1118179T1 (en) PHARMACEUTICAL COMPOSITION
CY1118374T1 (en) TRAMADOL CO-CRYSTALS AND NSAIDs
CY2015025I2 (en) METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE
CY1113963T1 (en) PHARMACEUTICAL COMPOSITIONS WHICH INCLUDE ACTIVIA-COMPETITORS AND USE THESE IN PREVENTION OR MULTIPLE
CY1115719T1 (en) NEW PHARMACEUTICAL COMBINATIONS FOR THE RESPIRATORY DISEASE TREATMENT
BRPI0407662B8 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
CL2007001918A1 (en) SUBSTITUTED HETEROARILY DERIVATIVE COMPOUNDS; METHOD FOR THE PREPARATION OF COMPOUNDS; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF PAIN, DEPRESSION, ALZHEIMER'S DISEASE AND HYPERTENSION BETWEEN OTHERS.
EA200601837A1 (en) PETROXASES FOR TREATMENT OF RESPIRATORY DISEASES
BRPI0508051A (en) heteroarylaminopyrazole derivatives usable for the treatment of diabetes
CL2008001024A1 (en) Phthalazinone derived compounds; pharmaceutical composition comprising said compound; and use of the compound for the treatment of cardiovascular diseases, parkinson's, inflammatory diseases, multiple sclerosis, cancer, among others
NO20085338L (en) Substituted 1,3-diphenylpropane derivatives, compositions and uses thereof
CL2007002382A1 (en) Use of compounds derived from 2,5-dihydroxybenzene for the treatment of skin cancer.
CY1115725T1 (en) UNIONS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF BETA-AMYLOIDIC DISEASES AND CONCLUSIONS
CL2008001820A1 (en) Aryl-isoxasol-imidazole derived compounds; preparation procedure; pharmaceutical composition containing them; and use in the preparation of useful drugs in the treatment of cognitive disorders and Alzheimer's-related diseases.
UA83691C2 (en) Use of substituted 2-aminotetralines for the preventative treatment of parkinson's disease
GT200600409A (en) USE OF AGOMELATIN TO OBTAIN PROPOSED MEDICINES FOR THE TREATMENT OF SLEEP DISORDERS IN THE DEPRESSED PATIENT.
CL2008000738A1 (en) COMPOUNDS DERIVED FROM MALONAMIDE; PROCESS FOR THE PREPARATION OF SUCH COMPOUNDS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE FOR THE TREATMENT OF DEPRESSION, PARKINSON AND ALZHEIMER'S DISEASE, BETWEEN OTHER DISEASES
CY1110130T1 (en) MORPHOLINE PRODUCTS FOR USE AS DOPAMINE AGONISTS IN THERAPEUTIC DISEASE Therapeutic Treatment I.A.
CY1116840T1 (en) USE 24-NORUDCA